NASDAQ:APYX
Apyx Medical Corp
Apyx Medical Corp's revenue grew 9.9% in fiscal 2025 to $52.8M while operating margin rose to −12.2%, its highest in 10 years. Free cash flow was −$9.1M, −17.2% of revenue.Summary generated from Apyx Medical Corp's SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$52.8M
Revenue growth+9.9%
Revenue, 5-yr CAGR+13.8%
Gross margin62.5%
Operating margin−12.2%
Net margin−21.2%
ROIC−25.3%
Return on equity−78.0%
Debt / equity2.58
Free cash flow−$9.1M
FCF margin−17.2%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 49 | 45 | 52 | 48 | 53 |
| Operating income | −14 | −24 | −17 | −19 | −6 |
| Net income | −15 | −23 | −19 | −23 | −11 |
| Free cash flow | −11 | −21 | −6 | −19 | −9 |
Recent filings
- 8-KOther events
Sep 29, 2026 - 8-KDirector or officer change
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KOther events
Jul 24, 2026 - 4Insider transaction report
Jul 2, 2026 - DEF 14AProxy statement
Jun 26, 2026 - 4Insider transaction report
Jun 17, 2026